argenx SE
ARGX817.320USD
+5.140+0.63%
收盘 10/24, 16:00（美东）报价延迟15分钟
49.99B总市值
39.04市盈率 TTM
关于 argenx SE 公司
argenx SE（前身为 arGEN X BV）是一家总部位于荷兰的生物制药公司。该公司主要致力于利用其发现平台 Simple Antibody 创建和开发用于治疗严重自身免疫性疾病的差异化抗体疗法产品线，该平台利用了骆驼免疫系统的特点。该公司开发了一系列专注于癌症和自身免疫适应症的抗体疗法产品线。它包括但不限于：Empasiprubart，一种针对 C2 的补体抑制剂，可阻断经典和凝集素途径的功能，同时保持替代途径完好无损，ARGX-119 是一种 MuSK 受体拮抗剂，具有多种神经肌肉适应症的潜力。
argenx SE简介
公司代码ARGX
公司名称argenx SE
上市日期Jul 10, 2014
CEOMr. Tim van Hauwermeiren
员工数量1599
证券类型Ordinary Share
年结日Jul 10
公司地址Laarderhoogtweg 25
城市AMSTERDAM
上市交易所Euronext Brussels
国家Netherlands
邮编1101 EB
电话31763030
网址https://www.argenx.com/
公司代码ARGX
上市日期Jul 10, 2014
CEOMr. Tim van Hauwermeiren
argenx SE公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Karl Gubitz
Mr. Karl Gubitz
Chief Financial Officer
Chief Financial Officer
500.00
--
Mrs. Camilla Sylvest
Mrs. Camilla Sylvest
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Tim van Hauwermeiren
Mr. Tim van Hauwermeiren
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
--
--
Dr. Ana Cespedes
Dr. Ana Cespedes
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Karen Massey
Ms. Karen Massey
Chief Operating Officer
Chief Operating Officer
--
--
Mrs. Andria Wilk
Mrs. Andria Wilk
Global Head of Quality
Global Head of Quality
--
--
Mr. Arjen Lemmen
Mr. Arjen Lemmen
Vice President - Corporate Development and Strategy
Vice President - Corporate Development and Strategy
--
--
Ms. Malini Moorthy
Ms. Malini Moorthy
General Counsel
General Counsel
--
--
Mr. Peter Ulrichts
Mr. Peter Ulrichts
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Peter K. M. Verhaeghe
Mr. Peter K. M. Verhaeghe
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Karl Gubitz
Mr. Karl Gubitz
Chief Financial Officer
Chief Financial Officer
500.00
--
Mrs. Camilla Sylvest
Mrs. Camilla Sylvest
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Tim van Hauwermeiren
Mr. Tim van Hauwermeiren
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
--
--
Dr. Ana Cespedes
Dr. Ana Cespedes
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Karen Massey
Ms. Karen Massey
Chief Operating Officer
Chief Operating Officer
--
--
Mrs. Andria Wilk
Mrs. Andria Wilk
Global Head of Quality
Global Head of Quality
--
--
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
暂无数据
地区USD
名称
营收
占比
United States
1.90B
86.56%
Rest of the World
161.25M
7.36%
Japan
89.39M
4.08%
China
43.52M
1.99%
Netherlands
153.00K
0.01%
业务
地区
暂无数据
股东统计
更新时间: 11 小时前
更新时间: 11 小时前
持股股东
股东类型
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
8.52%
T. Rowe Price Associates, Inc.
6.69%
Janus Henderson Investors
4.19%
Artisan Partners Limited Partnership
3.84%
Capital World Investors
3.19%
其他
73.56%
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
8.52%
T. Rowe Price Associates, Inc.
6.69%
Janus Henderson Investors
4.19%
Artisan Partners Limited Partnership
3.84%
Capital World Investors
3.19%
其他
73.56%
股东类型
持股股东
占比
Investment Advisor
31.17%
Investment Advisor/Hedge Fund
16.98%
Hedge Fund
5.02%
Research Firm
1.00%
Pension Fund
0.54%
Private Equity
0.39%
Bank and Trust
0.09%
其他
44.81%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
829
32.61M
53.31%
-4.28M
2025Q2
819
35.58M
58.18%
-2.01M
2025Q1
824
33.92M
55.61%
-3.84M
2024Q4
769
34.65M
57.94%
-3.60M
2024Q3
721
35.68M
59.67%
-2.04M
2024Q2
693
34.77M
58.16%
-2.15M
2024Q1
675
34.54M
58.16%
-754.92K
2023Q4
655
33.23M
56.14%
-574.05K
2023Q3
612
32.76M
56.24%
+237.83K
2023Q2
559
31.23M
55.80%
-1.48M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Fidelity Management & Research Company LLC
5.21M
8.52%
-251.10K
-4.59%
Jun 30, 2025
T. Rowe Price Associates, Inc.
4.09M
6.69%
-498.08K
-10.85%
Jun 30, 2025
Janus Henderson Investors
2.57M
4.19%
+422.32K
+19.71%
Jun 30, 2025
Artisan Partners Limited Partnership
2.35M
3.84%
-436.11K
-15.65%
Jun 30, 2025
Capital World Investors
1.95M
3.19%
+13.09K
+0.68%
Jun 30, 2025
Avoro Capital Advisors LLC
1.18M
1.92%
-60.18K
-4.87%
Jun 30, 2025
T. Rowe Price International Ltd
887.87K
1.45%
+93.47K
+11.77%
Jun 30, 2025
Citadel Advisors LLC
865.97K
1.42%
+314.03K
+56.90%
Jun 30, 2025
ClearBridge Investments, LLC
772.87K
1.26%
+108.50K
+16.33%
Jun 30, 2025
RTW Investments L.P.
673.50K
1.1%
--
--
Jun 30, 2025
查看更多
持股ETF
更新时间: 10月6日 周一
更新时间: 10月6日 周一
机构名称
占比
VanEck Biotech ETF
5.81%
iShares Neuroscience and Healthcare ETF
4.66%
First Trust NYSE Arca Biotechnology Index Fund
4.12%
Goldman Sachs Future Health Care Equity ETF
2.96%
iShares Biotechnology ETF
2.66%
PGIM Jennison International Opportunities ETF
2.63%
Janus Henderson US Sustainable Equity ETF
2.6%
Invesco Nasdaq Biotechnology ETF
2.29%
ProShares Ultra Nasdaq Biotechnology
2.29%
Tema Oncology ETF
1.96%
查看更多
VanEck Biotech ETF
占比5.81%
iShares Neuroscience and Healthcare ETF
占比4.66%
First Trust NYSE Arca Biotechnology Index Fund
占比4.12%
Goldman Sachs Future Health Care Equity ETF
占比2.96%
iShares Biotechnology ETF
占比2.66%
PGIM Jennison International Opportunities ETF
占比2.63%
Janus Henderson US Sustainable Equity ETF
占比2.6%
Invesco Nasdaq Biotechnology ETF
占比2.29%
ProShares Ultra Nasdaq Biotechnology
占比2.29%
Tema Oncology ETF
占比1.96%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
